Using systematic reviews to identify research gaps - a case study: mIBG for the treatment of neuroblastoma in children
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1745-6215
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Using systematic reviews to identify research gaps - a case study: mIBG for the treatment of neuroblastoma in children ; volume:14 ; number:1 ; day:29 ; month:11 ; year:2013 ; pages:1 ; date:11.2013
Trials ; 14, Heft 1 (29.11.2013), 1, 11.2013
- Urheber
-
Wilson, Jayne
- Beteiligte Personen und Organisationen
-
Gains, Jenny
Moroz, Veronica
Gaze, Mark
Wheatley, Keith
SpringerLink (Online service)
- DOI
-
10.1186/1745-6215-14-S1-P126
- URN
-
urn:nbn:de:1111-2016050233697
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wilson, Jayne
- Gains, Jenny
- Moroz, Veronica
- Gaze, Mark
- Wheatley, Keith
- SpringerLink (Online service)
Ähnliche Objekte (12)
Neuroblastoma : mIBG in its diagnosis and management
Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
123I metaiodobenzylguanidine (MIBG) uptake predicts early relapse of neuroblastoma using semi-quantitative SPECT/CT analysis
Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake
Analysis of quantitative [I-123] mIBG SPECT/CT in a phantom and in patients with neuroblastoma
123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel
Targeted deep sequencing to identify novel blood biomarkers of neuroblastoma
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma
Integrative genomic analyses identify neuroblastoma risk genes involved in neuronal differentiation
Dynamic planar scintigraphy for the rapid kinetic measurement of myocardial 123I-MIBG turnover can identify Lewy body disease
Impact of mediastinal, liver and lung 123I-metaiodobenzylguanidine (123I-MIBG) washout on calculated 123I-MIBG myocardial washout
Internal medicine residents identify gaps in medical education on outpatient referrals
Neuroblastoma : mIBG in its diagnosis and management
Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
123I metaiodobenzylguanidine (MIBG) uptake predicts early relapse of neuroblastoma using semi-quantitative SPECT/CT analysis
Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake
Analysis of quantitative [I-123] mIBG SPECT/CT in a phantom and in patients with neuroblastoma
123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel
Targeted deep sequencing to identify novel blood biomarkers of neuroblastoma
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma
Integrative genomic analyses identify neuroblastoma risk genes involved in neuronal differentiation
Dynamic planar scintigraphy for the rapid kinetic measurement of myocardial 123I-MIBG turnover can identify Lewy body disease
Impact of mediastinal, liver and lung 123I-metaiodobenzylguanidine (123I-MIBG) washout on calculated 123I-MIBG myocardial washout
Internal medicine residents identify gaps in medical education on outpatient referrals
Neuroblastoma : mIBG in its diagnosis and management
Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
123I metaiodobenzylguanidine (MIBG) uptake predicts early relapse of neuroblastoma using semi-quantitative SPECT/CT analysis
Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake
Analysis of quantitative [I-123] mIBG SPECT/CT in a phantom and in patients with neuroblastoma
123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel
Targeted deep sequencing to identify novel blood biomarkers of neuroblastoma
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma
Integrative genomic analyses identify neuroblastoma risk genes involved in neuronal differentiation
Dynamic planar scintigraphy for the rapid kinetic measurement of myocardial 123I-MIBG turnover can identify Lewy body disease
Impact of mediastinal, liver and lung 123I-metaiodobenzylguanidine (123I-MIBG) washout on calculated 123I-MIBG myocardial washout